Semaglutide Shortage Status: Where Things Actually Stand

The FDA declared the semaglutide shortage resolved on February 21, 2025. The compounding pathway closed in April–May 2025. Here's the current status, the litigation that's still active, and what every patient navigating the post-shortage environment needs to know.

The current FDA status (as of April 29, 2026)

Always verify current status at FDA's official drug shortage database — status can change as supply and demand evolve. The official tracker is at accessdata.fda.gov/scripts/drugshortages/.

How the semaglutide shortage actually played out

Why the shortage happened in the first place

Wegovy launched in June 2021 with strong launch demand. By early 2022, real-world prescription growth — driven by media coverage of off-label Ozempic use for weight loss and rapid awareness of Wegovy's clinical results — outpaced Novo Nordisk's manufacturing capacity for the auto-injector pen device. Ozempic followed onto the shortage list as off-label demand for the diabetes formulation grew alongside on-label prescribing.

Novo Nordisk responded by acquiring three Catalent contract-manufacturing facilities in 2024 for $11 billion, specifically to expand semaglutide and other peptide-injection capacity. By late 2024, Novo Nordisk reported all dose presentations of Wegovy and Ozempic were available — the data point FDA used to declare the shortage resolved.

What "shortage resolved" means legally

Under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies and outsourcing facilities are generally prohibited from producing drugs that are "essentially a copy" of a commercially available FDA-approved drug. There is one major exception: when the FDA-approved drug is on the FDA drug shortage list, compounders may produce essentially-copy versions to fill the supply gap.

When a shortage is declared resolved, the exception ends. Compounders that produce essentially-copy versions after the enforcement-discretion deadline expose themselves to FDA enforcement action.

What's still legal post-shortage

Compounded semaglutide is not entirely off the market. Compounders may still produce non-essentially-copy versions where there is documented clinical justification for the individual patient. Per FDA guidance, this can include:

• Removal of an inactive ingredient (excipient allergy)
• Different dosage form (e.g., oral or sublingual when injection is contraindicated)
• Different dosage strength not commercially available, with clinical justification
• Combination with another active ingredient creating a meaningfully different product
• Same drug, same dose, same route, different price — does not qualify under FDA guidance

Whether some current "compounded semaglutide" offerings actually meet the genuine-differentiation standard or are workarounds of the essentially-copy rule is the open enforcement question — and the subject of ongoing litigation.

What the litigation looks like

The Outsourcing Facilities Association (OFA) sued FDA over both the tirzepatide and semaglutide shortage-resolution determinations, arguing that the determinations were arbitrary and capricious. The cases are being heard in federal court in Texas. As of late April 2026, no preliminary injunction has been granted that would reinstate broader compounding pathways. The litigation will likely continue through 2026 and may shape the long-term regulatory framework for compounded peptide therapy.

Why this matters for patients

The end of the semaglutide shortage has three direct patient consequences:

1. Higher out-of-pocket cost for many patients

Compounded semaglutide had been available through telehealth for $200–400 per month. Brand-name Wegovy retail pricing approaches $1,300/month without insurance, though Novo Nordisk's NovoCare direct-pay program offers Wegovy at $499/month for cash-pay patients. Insurance coverage for weight-management indication remains highly variable.

2. Transition disruption

Patients on long-term compounded semaglutide who needed to transition to FDA-approved versions faced practical obstacles in early-to-mid 2025: new prescriptions, new prior authorizations, dose-form differences (e.g., compounded vials vs Wegovy auto-injector pens), and coordination between prescribers and dispensing pharmacies.

3. Renewed brand-name market dominance

With compounded essentially-copies legally restricted, the market shifted back toward Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro). Both manufacturers expanded direct-pay programs in 2025 in response to the post-compounding pricing dynamics.

How to verify current status yourself

Three official sources, in order of authority:

1. FDA Drug Shortages Database — accessdata.fda.gov/scripts/drugshortages/ — the only authoritative source for current shortage status
2. FDA Drug Shortage Communications — official FDA announcements about resolution declarations and enforcement discretion timelines
3. Manufacturer supply notices — Novo Nordisk and Eli Lilly each maintain investor and provider communications about supply availability

For patients who want FDA-approved brand-name access

What we'll be watching

Three things that could change the current status:

1. OFA litigation outcomes. A federal court ruling reinstating broader compounding pathways would significantly change the landscape.
2. Demand changes affecting supply. If demand grows faster than Novo Nordisk and Eli Lilly's expanded capacity, drugs could re-enter shortage status — which would re-open the compounding exception.
3. FDA enforcement against current compounded offerings. Cease-and-desist actions against compounders producing GLP-1 products under questionable "differentiation" justifications would clarify what remains legitimately permissible.

This page reflects FDA status as of April 29, 2026. For real-time verification, the FDA shortage database is the authoritative source.